Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

t of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, and the risks associated with conducting additional clinical trials for TRU-015, the uncertainty of the FDA approval process and the therapeutic and commercial value of Trubion's drug candidates; and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended June 30, 2007, and fr
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- Robbins & Myers, Inc. (NYSE: RBN ... its fiscal 2010 first quarter ending November 30, 2009, ... A live webcast is scheduled for ... Peter C. Wallace, President and Chief Executive Officer, ... Officer, will be discussing the Company,s performance and responding ...
(Date:12/15/2009)... LOUIS, Dec. 15 KV Pharmaceutical ... 2009, the Company received a written notice (the "Notice") ... 7/23/99, a stockholder of the Company, requesting that the ... a record date for stockholder action by written consent ... fill a vacant director seat resulting from Ronald J. ...
(Date:12/15/2009)... Dec. 15 SRI International, an independent ... award of U.S. patent 7,592,021 for a new ... of drugs through the human body,s mucous membranes. ... and allows for a much longer release time ... ,, Transmucosal delivery is an effective means to ...
Breaking Medicine Technology:KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 14449 1Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 14449 2Resverlogix Appoints A Brad Cann as Chief Financial Officer 14444 1Resverlogix Appoints A Brad Cann as Chief Financial Officer 14444 2Resverlogix Appoints A Brad Cann as Chief Financial Officer 14444 3MicroRNA Biomarkers Provide Reliable Diagnosis from Blood Samples 5428 1MicroRNA Biomarkers Provide Reliable Diagnosis from Blood Samples 5428 2
... 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, ... studies that,support the role of SPARC (secreted ... cancer and Abraxis' nanoparticle,albumin-bound (nab(TM)) tumor-targeting technology ... (AACR) Annual Meeting held,April 14-18, 2007 in ...
... Md., April 19, 2007 /PRNewswire-FirstCall/--,EntreMed, Inc. , ... treatment of cancer and inflammatory diseases,today announced ... novel cell cycle inhibitor. The data were ... for Cancer Research (AACR),Annual Meeting being held ...
Other Medicine Technology:Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 2Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 3Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 4Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway 5EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 2EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 3EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 4
(Date:12/16/2009)... Christmas rush Hallmark Cards have announced a great addition to ... an easy to navigate website at www.hallmark.co.uk/specialoccasions , customers can ... their own words and photos and then order as many copies ... ... Bradford, UK (PRWEB) December 16, 2009 -- Just in time ...
(Date:12/15/2009)... have successfully developed a new electrophoretic method for ... blood. The technique, using SARCOSYL-PAGE, has specifically ... the performance characteristics of SDS-PAGE for detecting other ... a grant from the World Anti-Doping Agency (WADA), ... Testing and Analysis published by Wiley-Blackwell. , ...
(Date:12/15/2009)... Food and Health Bureau has invited expressions of interest ... private hospitals at four sites in the Hong Kong ... March 31, 2010. ,, At a press conference, ... said the promotion of private hospital development was one ... Hong Kong government policy announced by Chief Executive Donald ...
(Date:12/15/2009)... Systems Group, a leading provider of Benefits Administration ... that it has completed a major V3 Benefits ... Pension & Health Plans (SAG-PH). ,, The new ... call center personnel in Burbank, Ventura and New ... Benefits Administration System which consolidated data from multiple ...
(Date:12/15/2009)... some sobering statistics concerning the parallel rise in diabetes and obesity ... means of combating this trend afflicting their workforce. , ... ... are climbing across America due in large part to the alarming ... Association has stated that the rate of diabetes could be cut ...
Breaking Medicine News(10 mins):Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 2Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 3Health News:The UK's Biggest Card Retailer Takes Choice and Value Personally 4Health News:Researchers discover novel method for detecting MIRCERA 2Health News:Hong Kong Government Invites Expressions of Interest in Development of Private Hospitals 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3
... to babies with low birth weight can significantly improve ... from infectious diseases. The research involved 1,154 full-term but ... most weighing 5 1/2 pounds or less. Mothers fed ... Fifteen of the 20 who died had not been ...
... such as those for hepatitis B, do not cause ... look at 768 diabetes-free children who were compared to ... been vaccinated against hepatitis B, whooping cough, chickenpox and ... diabetes than those who had not been given the ...
... proven effectiveness in long-term weight reduction and post potential ... more than a short time, accordinhg to an advisory ... published in: Journal of the American Heart Association. ... nutritionally rich foods such as fruits and vegetables, which ...
... study elderly patients who are depressed are more likely to ... depression is linked to poor physical health, and this relationship ... studied over 300 patients on hospital admission, tested then for ... who were depressed were 40 per cent more likely to ...
... tend to make a person better at remembering events? ... affirmative. This recent reasearch is reported in the jornal Neuropsychology. ... University of Toledo in Ohio, studied memory as a ... to be personally left-handed to share a unique trait: ...
... to the decrease in bone mineral density (BMD) that ... cause of fractures in the elderly. Previous research implicated cafeine ... retention. , As part of a larger long-term ... mineral density of women in high and low categories ...
Other Medicine News:Health News:High-protein diets may pose health risks 2
... INC. (CBI) Prolactin ELISA kit is used ... human serum or plasma. Human prolactin (lactogenic ... with a molecular weight of approximately 23,000 ... a solid phase direct sandwich ELISA method. ...
... Prolactin ELISA Kit is enzyme immunoassay ... Human Prolactin (PRL) concentration in serum. ... quantitative determination of many protein hormones ... accurate, sensitive, reproducible, rapid and specific ...
... This Enzyme-Linked Immunosorbent Assay (ELISA) serves the ... from plasma, serum and,urine. In a 1 ... samples is bound to an,available excess of ... to the surface of the microtitre plates. ...
... The AxSYM BNP assay allows you ... the status of your heart due ... versus NT-ProBNP. The AxSYM BNP assay ... simple, walk-away resultson a platform that ...
Medicine Products: